Regulations for Opdivo (Nivolumab) in Malignant Melanoma Treatment
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
In the field of melanoma treatment, the application of immune checkpoint inhibitors is constantly being optimized. According to the latest announcement from Ono Pharmaceutical Co., Ltd. in Japan, Opdivo (Nivolumab) has received approval in Japan for the treatment of "chemotherapy-naïve" (untreated) malignant melanoma patients. This is undoubtedly a significant milestone for many patients seeking advanced medical care in Japan.
Clinical Data: Significant Response Rates
The additional approval is primarily based on the results of two key clinical trials:
- ONE-4538-08 (Phase II Clinical Trial in Japan): Results from trials in Japanese patients showed a response rate (significant tumor shrinkage) of 29.2%.
- CA209-066 (International Clinical Trial): Overseas data further confirmed the superiority and safety of Opdivo in first-line treatment (without prior chemotherapy).
Latest Usage and Dosage Guidelines
According to the approved content, the usage of Opdivo is adjusted based on the patient's treatment history:
- First-line patients (without prior chemotherapy): The recommended dose is 3mg/kg (body weight), administered every two weeks.
- Patients with prior chemotherapy: The dose is 2mg/kg (body weight), with the option to administer every two or three weeks.
Mechanism of Immunotherapy and Economic Considerations
Opdivo works by blocking the interaction between PD-1 and PD-L1, reactivating suppressed T cells to attack cancer cells. Current clinical observations show that combining immune drugs with different mechanisms (such as Nivolumab combined with Ipilimumab) is more effective, though the corresponding side effects and financial burden also increase.
Cost Reference: In Japan, the price of Opdivo 100mg is approximately 390,000 Yen (excluding medical examination, customs, and shipping fees). Generally, four consecutive doses are required before an initial assessment of its effectiveness can be made. Due to the high cost, patients are advised to have an in-depth consultation with a professional medical team before making a decision.
Professional Support from Medical Supporter Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
#Melanoma #Opdivo #Immunotherapy #JapanMedical #OnoPharmaceutical #CancerTreatment
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.